Untitled

Upon realizing the potential of this route of administration, industry stakeholders have initiated several R&D efforts focused on exploiting the use of intranasal therapeutics as an effective modality for the treatment of various disorders.

 Roots Analysis has announced the addition of “Intranasal Drug Delivery Market” report to its list of offerings.

 Over the last few years, pharmaceutical companies have expanded their focus to devise novel intranasal drug delivery systems for the development of therapeutic candidates. This can be attributed to its numerous advantages such as, ease of administration, avoidance of first pass-metabolism and rapid onset of action, potentially making it an appealing alternative to other drug delivery systems.

 To order this 250+ page report, which features 120+ figures, please visit https://www.rootsanalysis.com/reports/intranasal-therapeutics-and-drug-delivery-systems.html

 Key Market Insights

 In addition to more than 10 approved products, over 65 drug candidates form a part of the development pipeline

Close to 60% of the pipeline candidates are currently being evaluated in clinical stages; of these, more than 15 drugs are in phase II studies. It is also worth highlighting that majority of the therapy candidates (55%) are small molecules.

 ~50 companies claim to be engaged in the development of intranasal therapeutics, globally

Of the total, 20% companies were established in this domain since 2016. Further, around 54% of the industry stakeholders are small companies. In addition, majority (80%) of the intranasal therapeutic developers are based in North America, primarily in the US.

 Presently, more than 40 intranasal drug delivery systems are available across different regions

40% of the intranasal drug delivery systems are available in unit and multi dose type of systems. This is followed by 20% intranasal drug delivery systems have metered dose type of system. It is worth highlighting that majority of the intranasal drug delivery systems are (53%) are present in liquid type of dosage form.

 More than 34,000 patients have been enrolled in over 130 clinical trials, worldwide

Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% have already been completed, while 16% are active and still recruiting patients.

 ~ 400 patents focused on intranasal therapeutics and drug delivery systems have been published, globally          

Owing to the rising research efforts of several industry and non-industry players engaged in this domain, close to 56% of patent applications have been filed post 2014. It is worth noting that, 235 patents related to intranasal therapeutics and drug delivery systems were filled / granted in the US alone.

 Close to 50 partnerships have been inked among various industry and non-industry players between 2016 and 2021

Maximum number of partnerships were established in 2020, indicating a recent rise in the interest of players engaged in this domain. It is worth mentioning that, majority (19%) of the deals were instances of product commercialization / distribution agreements, followed by technology utilization agreements (17%).

 Close to USD 5.5 billion has been invested by both private and public investors, since 2016

Of the total amount invested, over USD 1 billion was raised through debt financing, representing over 50% of the overall funding activity in this domain. Further, 11 instances of other equity were reported, wherein players collectively received funds worth more than USD 0.7 billion.

 North America is anticipated to capture over 85% of the global market share, in 2035

The market will be primarily driven by sales of intranasal small molecule therapeutics (91%), followed by those developed as biologics (9%). Further, intranasal therapies targeting dry eye diseases are expected to capture the dominant share (64.8%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future as well.

 To request a sample copy / brochure of this report, please visit link

 Key Questions Answered

§  Who are the key players engaged in offering intranasal therapeutics and drug delivery systems, across the world?

§  What are the key therapeutic indications for which intranasal therapeutics are being investigated?

§  What are the key geographies where research focused on intranasal therapeutics and drug delivery systems is being conducted?

§  What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?

§  How is the current and future market opportunity likely to be distributed across key market segments?

§  What are the anticipated future trends related to intranasal therapeutics and drug delivery systems market?

 The financial opportunity within the intranasal therapeutics market has been analyzed across the following segments:

§  Type of Molecule

Small     Molecules

Biologics

 §  Target Indication

Acute     Repetitive Clusters

Anaphylaxis

COVID-19

Dry     Eye Disease

Hypoglycemia

Influenza

Major     Depressive Disorder

Migraine

Nasal     Polyps

Prader-Willi     Syndrome

 §  Key Players

 §  Key Geographical Regions 

North     America

Europe

Asia     Pacific

 The research also includes detailed profiles of the companies (listed below) engaged in developing intranasal therapeutics and drug delivery systems; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.

§  Aptar Pharma

§  Nemera

§  Teleflex

§  Mystic Pharmaceuticals

§  Zeteo Biomedical

 For additional details, please visit

https://www.rootsanalysis.com/reports/intranasal-therapeutics-and-drug-delivery-systems.html or email [email protected]

 You may also be interested in the following titles:

1.      Single-use Sensors for Bioprocessing Market, 2021-2035

2.      At-Home Blood Collection and Micro Sampling Devices Market, 2021-2030

3.      Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030

 Contact:

Ben Johnson

+1 (415) 800 3415

Large Volume Wearable Injectors have made it convenient to self-administer drugs in the home care setting, providing substantial cost benefits, improving medication adherence and reducing the risk of dosing errors, microbial contamination and needle-stick injuries; in fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19).  

 Roots Analysis is pleased to announce the publication of its recent study, titled, “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices.”

 The report features an extensive study of the current market landscape, offering an informed opinion on the likely future evolution of these self-injection devices over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed review of the overall landscape of large volume wearable injectors market available for delivery of insulin and non-insulin drugs, in addition to the under development / available drug device combinations

§  An insightful competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power and product specifications

§  Elaborate profiles of the prominent companies that develop large volume wearable injectors.

§  An analysis of the partnerships that have been established in the period between 2015 and 2020.

§  A detailed analysis on acquisition targets.

§  An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors over the last three decades.

§  A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future

§  A social media analysis depicting prevalent and emerging  trends, and the popularity of large volume wearable injectors on Twitter

§  A detailed analysis of completed, ongoing and planned clinical trials

§  A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain

§  An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval, in general.

§  A detailed market forecast, featuring analysis of the financial opportunity within the large volume wearable injectors market (for delivery of non-insulin and insulin drugs) across the following segments:

Type     of Device

§  Patch Pump / Injectors

§  Infusion Pump / Injectors

  Product     Usability

§  Disposable

§  Re-usable

  Therapeutics     Area (for non-insulin drugs)

§  Neurological Disorders

§  Cardiovascular Disorders

§  Oncological Disorders

§  Infectious Disorders

Key     Geographical Regions 

§  North America

§  Europe

§  Asia-Pacific

 Key companies covered in the report:

§  Becton Dickinson

§  Bespak (subsidiary of Consort Medical)

§  CeQur

§  Debiotech

§  Eli Lilly

§  Enable Injections

§  Insulet

§  Medtronic

§  PharmaSens

§  Roche

§  SOOIL Development

§  Sonceboz

§  Sensile Medical (acquired by Gerresheimer)

§  SteadyMed Therapeutics (acquired by United Therapeutics)

§  Tandem Diabetes Care

§  Weibel CDS (acquired by SHL Medical)

§  West Pharmaceutical Services

 For more information, please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

 Other recent offerings:

1.        Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030 [COVID-19 Series]

2.      Global Autoinjectors Market (3rd Edition), 2020-2030

3.       Prefilled Syringes Market (5th Edition), 2020-2030

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

With over 85 microbiome-based, live biotherapeutic products under preclinical and clinical development, the demand for R&D and manufacturing services for such products is anticipated to increase beyond the capabilities of innovator companies alone

 London

 Roots Analysis has announced the addition of “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030” report to its list of offerings.

 Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.

 To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 Key Market Insights

 Over 25 players claim to provide microbiome-based live biotherapeutics contract manufacturing

More than 80% of the companies engaged in this domain are mid-sized and large firms; examples of firms established in 2019 include Arranta Bio and BacThera (a Lonza and Chr. Hansen joint venture). Further, nearly 50% of the CMOs have established the necessary expertise for handling both anaerobic and aerobic strains.

 35+ manufacturing facilities focused on live biotherapeutics have been established worldwide

Majority (~55%) of the manufacturing facilities are located in Europe, followed by North America. Prominent manufacturing hubs in the Europe include (in decreasing order of number of manufacturing facilities) the UK, France, the Netherlands, Italy, Germany, Switzerland, and Sweden.

 Approximately 88% of the total installed capacity is dedicated to commercial scale manufacturing  Whereas, rest (~10%) of the capacity is being used for preclinical / clinical scale manufacturing of microbiome products. In addition, over 60% of the total current global, installed manufacturing capacity is installed in Europe.

 Over 170 registered clinical trials involved the use of microbiome-based live biotherapeutics

Majority of these studies are being conducted at various hospitals / centers across the US. Examples of leading non-industry players include (in decreasing order of number of trials) University of California, National Institute of Allergy and Infectious Diseases, Radboud University, and The University of Texas Health Science Center.

 The global clinical demand for microbiome-based live biotherapeutic products is anticipated to grow at a CAGR of 23%, between 2020 and 2030

By 2030, over 31,000 patients are estimated to be enrolled in the clinical trials involving the use of microbiome-based live biotherapeutics. Industry players are anticipated to contribute majority (over 60%) of the demand in the short-term as well as long-term.

 Several big pharma players are actively engaged in the microbiome live biotherapeutics domain

In fact, leading pharmaceutical companies have partnered with smaller business entities to develop manufacturing capabilities related to microbiome-based therapies / diagnostics. Examples of such small ventures with players with in-house capability include (in alphabetical order) Assembly Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.

 By 2030, North America and Europe are anticipated to capture over 85% of the market opportunity

In terms of type of product manufactured, APIs currently represent the highest share (58%); this trend is unlikely to change in the foreseen future.

 To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/306/request-sample.html

                                                                                     Key Questions Answered

§  Who are the leading CMOs offering microbiome contract manufacturing services, across the world?

§  What are the key challenges faced by microbiome contract manufacturers?

§  Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?

§  What is the annual clinical demand for microbiome-based live biotherapeutic products?

§  What is the current, installed contract manufacturing capacity for live biotherapeutics?

§  What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?

§  What are the various initiatives undertaken by big pharma players in this domain?

§  What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?

§  How is the current and future market opportunity likely to be distributed across key market segments?

§  What are the anticipated future trends related to live biotherapeutics manufacturing?

 The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:

§  Type of Product Manufactured

§  Active Pharmaceutical Ingredients (APIs)

§  Finish Drug Formulations (FDFs)

 §  Type of Type of Formulation

§  Solid Formulations

§  Oral Liquids

§  Injectables

§  Others

 §  Scale of Operation

§  Clinical

§  Commercial

 §  Company Size

§  Small-sized

§  Mid-sized

§  Large

 §  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

 The report features inputs from eminent industry stakeholders, according to whom the microbiome therapeutics contract manufacturing services market is likely to witness substantial growth in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:

§  Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)

§  Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)

§  Assaf Oron (Chief Business Officer, BiomX)

§  Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)

§  Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)

§  JP Benya (Vice President, Business Development, Assembly Biosciences)

§  Rob van Dijk (Business Development Manager, Wacker Biotech)

§  Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)

 The research covers detailed profiles brief profiles of several companies (including those listed below); each profile features an overview of the company, its financial information (if available), microbiome-related service portfolio, facilities dedicated to microbiome manufacturing, and an informed future outlook.

§  Biose®

§  BJP Laboratories

§  Capsugel (acquired by Lonza)

§  Cerbios-Pharma

§  Cobra Biologics (acquired Cognate Bioservices)

§  Inpac Probiotics

§   Paragon Bioservices (a unit of Catalent Biologics)

§  UAS Labs

 For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email [email protected]

 You may also be interested in the following titles:

1.     HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030

2.     Antibody Contract Manufacturing Market, 2020 – 2030

3.     The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

 About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

Over the years outsourcing has become a popular trend among medical device developers, allowing such companies to leverage the expertise / substantial production capabilities of CMOs / CDMOs in order to gain cost and time related benefits

 Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device Contract Manufacturing Market”.

 The report features a comprehensive study on the current landscape of contract manufacturing service providers focused on medical devices (specifically for drug-delivery devices, diagnostic devices and therapeutic devices). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed review of the overall landscape of the medical device contract manufacturing companies, featuring a list of CMOs engaged in this domain. 

§  Medical device CMOs are actively engaged in aligning their operations to comply to the standards established by various global and regional regulatory bodies

§  An elaborate discussion on the future opportunities / trends related to the medical device industry.

§  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.

§  An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval, across different countries.

§  A benchmark analysis, highlighting the key focus areas of small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.

§  An analysis of the medical device supply-chain, highlighting the role of CMOs engaged in this domain.

§  Elaborate profiles of popular players that specialize in providing services for both precommercial and commercial scale manufacturing of medical devices.

§  A geographical clinical trial analysis of ongoing and planned studies related to medical devices.

§  A detailed analysis of the mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Application areas

§  Therapeutic devices

§  Diagnostic devices

§  Drug delivery devices

§  Other devices

§  Device class

§  Class I medical devices

§  Class II medical devices

§  Class III medical devices

§  Therapeutic areas

§  Cardiovascular disorders

§  CNS disorders

§  Metabolic disorders

§  Oncological disorders

§  Orthopedic disorders

§  Ophthalmic disorders

§  Pain disorders

§  Respiratory disorders

§  Other therapeutic areas

§  Key geographical regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the world

Key companies covered in the report

§  Cirtec Medical

§  Creganna Medical

§  DynaFlex Technologies

§  Europlaz Technologies

§  Interplex

§  I-Tek Medical Technologies

§  Keystone Solutions Group

§  Modern Medical

§  Oscor

§  Providence Enterprise

§  Riverside Medical Packaging

§  SMC

§  Stellartech

§  Suzhou Jenitek

§  Synecco

§  Trelleborg Sealing Solutions

 For more information please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/medical-device-contract-manufacturing-market-2019-2030/258.html

 Other Recent Offerings

1.      Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices

2.      Medical Device CROs Market (2nd Edition), 2020 - 2030

3.      Global Autoinjectors Market (3rd Edition), 2020-2030

4.      Medical Device Labels Manufacturing Market, 2019 - 2030

 About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

Over the years, outsourcing has become a popular trend with the medical device industry, allowing innovators to leverage the technical and regulatory expertise of contract service providers in order to expedite time to market

 Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CROs Market, 2019-2030.”

 The report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices. The study features an in-depth analysis, highlighting the capabilities of the various CROs engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

§  A detailed review of the current Medical Device CRO market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain.

§  A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies.

§  An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, Asia-Pacific and rest of the world.

§  Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies.

§  A benchmark analysis, highlighting the key focus areas of very small-sized, small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.

§  An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.

§  An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.

§  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 §  Medical Device Class

§  Class I

§  Class II

§  Class III

 §  Therapeutic Area

§  Cardiovascular Disorders

§  CNS Disorders

§  Metabolic Disorders

§  Oncological Disorders

§  Ophthalmological Disease

§  Orthopedic Disorders

§  Pain Disorders

§  Respiratory Disorders

§  Others

 §  Type of Regulatory Affairs Service

§  Pharmacies GAP-Analysis

§  Pharmacies Legal Representation

§  Pharmacies Notified Body Selection

§  Product Labelling-related Services

§  Product Registration and Clinical Trial Applications

§  Regulatory Document Submissions

§  Regulatory Writing and Publishing

§  Risk Management-related Services

§  Technical Dossier Set-up

§  Vigilance & Medical Device Report

 §  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

 Key companies covered in the report

§  CTI Clinical Trial and Consulting Services

§  CROMSOURCE

§  ICON

§  Intertek

§  Medpace

§  MIC Medical

§  North American Science Associates (NAMSA)

§  Parexel

§  PharmaLex

§  Premier Research 

§  Société Générale de Surveillance (SGS)

§  Underwriters Laboratory (UL)

 For more information please click on the following link

https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html  

 Other Recent Offerings

1.       Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030

2.       Medical Device Labels Manufacturing Market, 2019-2030

3.       Medical Device Contract Manufacturing Market, 2019-2030

 About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

Outsourcing the manufacturing of labels is a popular trend among medical device developers, enabling such companies to leverage the advanced capabilities of CMOs, while focusing on the core aspects of product development

 Roots Analysis has announced the addition of “Medical Device Labels Technology Market, 2019-2030” report to its list of offerings.

 The report features an extensive study of the current market landscape of companies offering manufacturing services for medical device labels. The study also features detailed analysis and an elaborate discussion on the future potential of this evolving market. Owing to the ever-increasing number of medical devices along with the rising associated complexities and stringent guidelines issued by various regulatory authorities, the global medical device labeling market is likely to grow at stable rate.  Amongst other elements, the report includes:

§  A detailed assessment of the overall landscape of companies offering manufacturing services for medical device labels.

§  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the key value drivers of such deals inked between 2014 and 2019 (till June).

§  A detailed acquisition target analysis, which takes into consideration the historical trend of activity of top acquirers, providing a means for industry stakeholders to identify potential acquisition targets.

§  An industry-wide benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies.

§  A detailed business portfolio analysis based on the 9-box attractiveness and competitiveness (AC) matrix framework, highlighting the current market attractiveness and competitive strength of different printing technologies used by label manufacturers.

§  An elaborate discussion on the various guidelines established by major regulatory bodies, governing medical device labeling-related practices and product approval, across different countries.

§  Elaborate profiles of key players that claim to have a diverse range of capabilities for the manufacturing of different types of labels for medical devices.

§  A discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework.

§  A review of the various upcoming opportunities and anticipated future trends related to medical device label manufacturing that are expected to influence the evolution of this industry over the coming years.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of labels

§  Glue applied labels

§  Pressure sensitive labels

§  In mould labels

§  Shrink sleeve labels

§  Other labels

 §  Type of material

§  Plastic labels

§  Paper labels

§  Other material labels

 §  Application type

§  Monitoring and diagnostic equipment labels

§  Disposable consumables labels

§  Therapeutic equipment labels

§  Device class

§  Class I medical devices

§  Class II medical devices

§  Class III medical devices

 §  Key geographical regions

§  North America

§  Europe

§  Asia Pacific

 Key companies covered in the report

§  Avery Dennison

§  Faubel

§  Huhtamaki

§  Iwata Label

§  Labeltape

§  Matform

§  Maverick Label

§  Mondi Group

§  Multi-Color

§  OPM Group

§  Resource Label Group

§  Schreiner Group

§  Steven Label

§  Topflight

§  WS Packaging

 For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/medical-device-labels-manufacturing-market-2019-2030/272.html

 Other Recent Offerings

1. Global Handheld Ultrasound Imaging Devices Market, 2020-2030

2. Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

3. Medical Devices CROs Market (2nd Edition), 2019-2030

 About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

Off-site, modular construction minimizes disruption to building timelines and logistical delays, ensuring systematic delivery of new facilities, this is particularly beneficial within the healthcare industry, where speed, sanitation and sterility are crucial

 Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market”

 The report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

 §  An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers.

§  A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications.

§  An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021.

§  An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. 

§  An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players.

§  Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. 

§  An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.

§  A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Modular biomanufacturing : Moreover, biopharma industry continues to seek innovative ways of optimizing drug development costs and timelines. Off-site design and modularization demonstrate great potential to provide the industry with the agility to reduce the overall time to market for a particular product.

 To Request Sample Page - https://www.rootsanalysis.com/reports/178/request-sample.html

 §  Type of Modular Construct 

§  Hybrid Skid

§  Plug-and-Play

§  Skid-Mounted

§  Truckable

§  Others

§  Type of Construction Component

§  Base Building

§  Electrical System

§  Mechanical System

§  Process Equipment

§  Process Piping

§  Process Utilities

§  Other Components

§  Purpose of Facility

§  Aseptic Filling

§  Manufacturing

§  Research and Development

§  Others

§  Facility Area

§  Very Small

§  Small

§  Mid-Sized

§  Large

§  Very Large

§  Scale of Operation

§  Clinical

§  Commercial

§  Type of Industry

§  Pharmaceutical                  

§  Biotechnology

§  Type of Product

§  Biosimilars                        

§  Cell and Gene Therapies

§  Monoclonal Antibodies

§  Vaccines

§  Other Products

§  Type of Facility

§     New Facility

§     Facility Expansions

§  Key Geographical Regions

§  North America                  

§  Europe

§  Asia

§  Middle East and North Africa

§  Latin America

§  Rest of the World

 Download Free Insights now - https://www.rootsanalysis.com/reports/178/free-insights.html

 Transcripts of interviews held with the following senior level representatives of stakeholder companies

Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)

§  François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)

§  Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)

§  Pär Almhem (President, Modwave)

§  Sulogna Roy (Ex Sales Manager, Zeton)

§  Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

 Key companies covered in the report

§  Cytiva

§  G-CON Manufacturing

§  Pharmadule Morimatsu

§  NNE

§  IPM Technologies

§  KeyPlants

§  Germfree Laboratories

§  ModuleCO Pharma

 For more information, please click on the following link

https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html

 You may also be interested in the following titles:

1.      Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030

2.      Biopharmaceutical CROs Market, 2021-2030

3.      Continuous Manufacturing Equipment Providers Market, 2021-2030

4.      DNA-Encoded Libraries: Platforms and Services Market

5.      Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

With the recent FDA approval of Tavenos™ for ANCA-associated vasculitis, myeloid cells have become an attractive target for pharmacological interventions, being developed for the treatment of various oncological disorders

 London

 Roots Analysis has announced the addition of “Myeloid Cell Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

 With ever increasing cancer burden, the focus of the research community has shifted towards the development of alternatives for the traditional anticancer therapies, such as myeloid cell targeting therapeutics. Myeloid cells, with their multifaceted functions and abundance in tumor microenvironment can be easily targeted and have emerged as novel therapeutic candidates for the treatment of several oncological disorders in combination with chemotherapy and radiotherapy.

 To order this 150+ page report, which features 100+ figures and 5+ tables, please visit

https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

 Key Market Insights

 Presently, more than 100 drug candidates are being evaluated across different phases of development

Over 70% of the pipeline candidates are currently being evaluated in clinical stages; of these, more than 35 candidates are in phase I of their clinical trials. This is followed by 25% therapies being investigated in preclinical and discovery stages. It is worth highlighting that majority of the therapy candidates (53%) are biologics.

 More than 380,000 patients have been enrolled in over 1,500 clinical trials, worldwide

Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% have already been completed, while 22% are active and still recruiting patients.

 Close to 10,000 articles focused on myeloid cells have been published, since 2016

Owing to the rising research efforts by several industry and non-industry players engaged in this domain, a number or peer reviewed articles have been published in reputed scientific journals. It is worth highlighting that, in 2021 (till June) 935 articles related to myeloid cells targeting therapeutics were published; of these more than 70% are research articles.

  North America and Europe are anticipated to capture larger share of the market share by 2035

Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of oncological and rare disorders. It is worth mentioning that myeloid cells targeting therapeutics market for small molecules is likely to capture over 70% of the total market share by 2035.

 To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

 Key Questions Answered

§  Who are the leading players engaged in the development of myeloid cells targeting therapeutics?

§  Which are the key drugs being developed across early and late stages of development?

§  Which companies are actively involved in conducting clinical trials for myeloid cell targeting therapeutics?

§  What is the focus of various publications related to therapeutics targeting myeloid cells?

§  What kind of partnership models are commonly adopted by industry stakeholders engaged in the myeloid cells targeting therapeutics domain?

§  How is the current and future opportunity likely to be distributed across key market segments?            

 The financial opportunity within the myeloid cells targeting therapeutics market has been analyzed across the following segments:

§  Type of Molecule

Small     Molecule

Biologics

 §  Type of Therapeutic Area

Oncological     Disorders

Rare     Disorders

 §  Type of Therapy

§  Combination Therapy

§  Monotherapy

 §  Route of Administration

Intravenous

Oral

 §  Key Geographical Regions 

North     America

Europe

Asia     Pacific

 The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the development of myeloid cells targeting therapeutics. The report includes detailed transcripts of the discussions held with the following industry experts:

§  Rene Hoet (Chief Scientific Officer, Montis Biosciences)

§  Tom Wilton (Chief Business Officer, Carisma Therapeutics)

  The research also includes detailed profiles of the companies (listed below) engaged in developing therapies targeting myeloid cells; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.

§  AstraZeneca

§  ChemoCentryx

§  Daiichi Sankyo

§  Enlivex

§  Gilead

§  GlaxoSmithKline

§  Immune-Onc Therapeutics

§  Infinity Pharmaceuticals

§  Jansen

§  Macrophage Pharma

§  Pfizer

§  Roche

  For additional details, please visit

https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html or email [email protected]

 You may also be interested in the following titles:

1.    Squamous Non-Small Cell Lung Cancer Market, 2021-2031

2.    Novel T-Cell Immunotherapies Market, 2021-2030

3.    HER2 Targeting Therapies Market, 2021-2030

 Contact:

Ben Johnson

+1 (415) 800 3415

In the past few years, there has been a significant surge in the demand for recombinant proteins and cellular systems for biomedical research, diagnostics and different therapies. In order to support the large- scale production and manufacturing of such cell- based products, there is an imperative need for the efficient development of high- quality stable cell lines. In fact, 60-70% of manufacturing processes of available biologics require live mammalian systems. A cell line refers to a defined population of cells that originates from a single common ancestor cell and have the ability to retain stable phenotypes and functions.  In general, once the primary culture is sub-cultured, it becomes a cell line.

 To request a sample copy / brochure of this report, please visit : https://www.rootsanalysis.com/reports/cell-line-development-and-characterization-services/request-sample.html

 Cell lines have revolutionized scientific R&D and are currently being used for a myriad of applications.

 The development and characterization of cell lines is both technically challenging and financially demanding. It requires cost intensive materials, specialized genetic engineering technologies, aseptic cell culturing conditions, specialized infrastructure for cell storage, and product-specific analytical techniques for cell / cell line testing. Recent years have witnessed the emergence of a large number of highly qualified contract research organizations (CROs), contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that assist drug developers and researchers, and offer the following benefits:

§  Reduction of economic burden: Cost of developing and characterizing cell lines may vary between few thousand dollars to hundreds of thousands of dollars, depending on the cell line engineering methods, expression hosts, upstream and downstream process development and the type of tests required during research and / or the production phases. For instance, cell lines edited using CRISPR/Cas9 system are likely to be priced higher. Service providers have the potential to reduce the financial risk for the stakeholders that do not have the capacity, capability or the in-house expertise to carry out such operations.

§  Enables companies to focus on research: Contract service providers offer a variety of services for different cell lines, allowing developers and researchers to avail analytical tests as per their requirements. Therefore, outsourcing cell line development and characterization operations allows product developers to focus their efforts on R&D activities.

§  Knowledge expertise: Service providers have the necessary skillset to carry out complicated procedures in minimum time with reduced chances of failure. In addition, these organizations often provide consulting services to assist researchers to obtain accurate results and address regulatory concerns.

§  Risk Sharing: One of the crucial factors determining the net outcome of any industrial process is risk-analysis. Outsourcing few of the components of an industrial process is just like shifting certain responsibilities to the outsourced vendor. Henceforth, it is a mutual understanding between the companies to handle the risk factors in a better way.

§  Integrated offerings: Nowadays, contract services providers are offering full range services, from cell line generation to screening and characterization, including the establishment and maintenance of master cell banks (MCBs) and working cell banks (WBCs), along with the end-product formation from cell lines.

Despite the increasing opportunity in this domain, high entry costs (associated with building the required technical expertise and setting up of facilities) and rising regulatory stringencies, are the primary impediments to the number of stakeholders entering this market. For sponsors looking to outsource, there are multiple areas of concern associated with engaging service provider entities; some of the prominent challenges faced, include lack of necessary expertise for substandard cell growth troubleshooting, and process transfer related complexities. The selection of an inappropriate service provider partner can prove to be disastrous in the long run, creating issues, such as delays and cost overruns.  

 Despite the aforementioned challenges, the growing demand for novel biologics, especially amidst COVID-19 pandemic, impending patent expiries of several blockbuster biologics, growing popularity of regenerative medicines and cellular vaccines, and advancements in genetic engineering and bioanalytical technologies, are some of the major factors that are anticipated to drive the growth of cell line development and characterization services market, in the mid to long term.

 Key Questions Answered

Who are the leading players offering     cell line development services?

What kind of CDMO support is     available for cell line development, across different regions?

What are the common sources, gene     delivery methods, protein yield and affiliated services offered by the     cell line development service providers?

Who are the leading industry and     non-industry players offering cell line     characterization services?

What are the most popular services     offered for characterization of cell lines?

Which partnership models are     commonly adopted by stakeholders in this industry?

How is the current and future     opportunity likely to be distributed across key market segments?

What are the anticipated future     trends related to cell line development and characterization market?

 For additional details, please visit : https://www.rootsanalysis.com/reports/cell-line-development-and-characterization-services.html

  You may also be interested in the following titles:

1.      RAS Targeting Therapies Market, 2021-2031

2.      Novel T-Cell Immunotherapies Market, 2021-2030

3.      HER2 Targeting Therapies Market, 2021-2030

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Key Inclusions

§  A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, cell encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications.

§  Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the in the foreseen future.

§  An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.

§  A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.

§  An analysis of the partnerships that have been established in the domain in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.

§  An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area.

§  A detailed study on the various grants that have been awarded to research institutes in this field.

§  An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength.

 The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

§  Type of licensing deal payment

§   Upfront payment

§   Milestone payment

 §  Therapeutic area

§   Metabolic disorder

§   Neurological disorder

§   Ophthalmic disorder

§   Oncological disorder

 §  Target disease indication

§   Ataxia telangiectasia

§   Breast cancer

§   Diabetes

§   Glaucoma

§   Head and neck cancer

§   Macular telangectasia

§   Pancreatic cancer

§   Parkinson's disease

§   Retinitis pigmentosa

 §  Type of encapsulation material used

§   Alginate-based microcapsule

§   Cellulose hydrogel

§   Medical-grade plastic

§   Red blood cell

 §  Key geographical region

§   North America

§   Europe

§   Asia-Pacific and rest of the world

 To request sample pages, please visit this - https://www.rootsanalysis.com/reports/249/request-sample.html

 Key Questions Answered

§  What are the prevalent R&D trends related to cell encapsulation techniques?

§  Which clinical conditions can be treated using encapsulated cell therapy products?

§  What are the key challenges faced by stakeholders engaged in this domain?

§  What are the key technology platforms that leverage the concept of cell encapsulation?

§  Who are the leading industry and non-industry players in this market?

§  What are the key geographies where research on encapsulated cell therapies is being conducted?

§  Who are the key investors in this domain?

§  Who are the key thought leaders with expertise in cell encapsulation technologies?

§  What kind of partnership models are commonly adopted by industry stakeholders?

§  Who are the potential strategic partners (for instance, manufacturers) for encapsulated therapy developers?

§  How is the current and future market opportunity likely to be distributed across key market segments?

§  What are the factors that are likely to influence the evolution of this upcoming market?

 For additional information  - https://www.rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030-/249.html

  You may also be interested in the following titles:

1.    Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices

2.    Endocannabinoid System Targeted Therapeutics Market, 2020-2030

3.    Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

 Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

The approval and success of Soliris® and other complement therapeutics has paved for the development of several drugs targeting different pathways of complement system for the treatment of a wide range of disease conditions

 London

 Roots Analysis has announced the addition of “Next Generation Complement Therapeutics market, 2022-2035” report to its list of offerings.

 The potential of complement therapeutics to ease the treatment of complement-associated diseases has greatly expedited the progress of these therapeutics into clinical stages of development. Since the complement system is a complex and multidimensional system, many different therapeutic targets are likely to be discovered for a variety of disease indications, such as paroxysmal nocturnal hemoglobinuria, hereditary angioedema, renal diseases and several others, in the future. The main focus is to develop innovative therapies targeting proteins other than C5, with reduced cost and increased safety.

 To order this 190+ page report, which features 200+ figures and 30+ tables, please visit https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html

 Key Market Insights

 Presently, 190+ complement therapeutics have been marketed / are being evaluated across different phases of development for the treatment of various disease indications

Close to 80% of the pipeline candidates are under clinical evaluation. Further, therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO®, have been approved for the treatment of Hereditary Angioedema. Majority (84%) of these candidates are biologics, followed by small molecules (16%).

 Around 50 industry and non-industry players are engaged in the development of next generation complement therapy

North America has emerged as the hub, featuring the presence of approximately 50% developers. The market is currently dominated by the presence of mid-sized players (37% of the total number of stakeholders). Interestingly, 15% of the players are big pharma companies engaged in the development of such therapeutics for multiple therapeutic areas.

 More than 850 clinical trials have been registered for the evaluation of next generation complement therapeutics, worldwide

The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, during the period 2017-2021 (till October). Of the total number of trials registered, close to 60% have already been completed, while 24% of the studies are actively recruiting participants.

 Close to 1,450 articles related to next generation complement therapeutics, have been published in reputed scientific journals, since 2017

More than 40% of the articles focused on next generation complement therapeutics were published post-2019. Popular journals that have published multiple articles include Frontiers in Immunology, Allergy & Asthma Proceedings, Journal of Immunology and Molecular Immunology.

 Close to 1,250 grants have been awarded to support research on next generation complement therapeutics, since 2017

Grants worth USD 835 million have been awarded to various companies / organizations working in this domain during 2017-2021. Around 20% of the grants were funded by the National Cancer Institute.

 Over 3,490 patents have been filed / granted related to next generation complement therapeutics, since 2016

More than 650 patents were filed / granted in 2021 (till November). Further, around 45% of the patents were filed in Europe It is worth highlighting that majority of the patents were granted / filed for indications, including angioedema, meningitis, microangiopathy, neuromyelitis optica, periodontitis and psoriasis.

 Partnership activity in this field has increased at a CAGR of nearly 55%, between 2017 and 2021 (till November)

More than 45% of the reported deals were product development and commercialization agreements. Further, majority of the agreements were signed by players based in North America (66%).

 Close to USD 14 Billion has been invested by both public and private investors for the development of next generation complement therapeutics

Around 40% of the companies engaged in this domain primarily received funding through secondary offerings. Further, 70% of the funding instances were reported by players headquartered in North America.

 North America is anticipated to capture over ~80% of the global market share for phase III complement therapeutics, by 2035

In 2035, close to XX% of the market revenues are expected to be generated from sales of therapeutics intended for infectious diseases. Further, therapies designed for subcutaneous route of administration are expected to occupy a larger share (XX%) of the overall market in 2035.

 To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html

                                                                                     Key Questions Answered

§  Who are the leading industry and non-industry players engaged in the development of next generation complement therapeutics?

§  Which are the key drugs being developed across early and late stages of development?

§  Which geographies are the most active in conducting clinical trials related to next generation complement therapeutics?

§  What is the focus area of various publications related to the next generation complement therapeutics?

§  Which are the leading funding institutes / centers supporting the research related to next generation complement therapeutics?

§  What kind of partnership models are commonly adopted by industry stakeholders?

§  Who are the key investors, active in the field of next generation complement therapeutics?

§  What are the different initiatives undertaken by big pharma players for the development of next generation complement therapeutics in the recent past?

§  How is the current and future market opportunity, related to next generation complement therapeutics likely to be distributed across key market segments?

 The financial opportunity within the next generation complement therapeutics market has been analyzed across the following segments:

§  Target Disease Indication

§  Atypical Hemolytic Uremic Syndrome

§  Cardiac Transplantation Rejection

§  Cold Agglutinin Disease

§  COVID-19

§  Generalized Myasthenia Gravis

§  Guillain-Barre Syndrome

§  Hereditary Angioedema

§  Neuromyelitis Optica

§  Paroxysmal Nocturnal Hemoglobinuria

 §  Therapeutic Area

§  Cardiovascular Disorders

§  Genetic Disorders

§  Hematological and Vascular Disorders

§  Infectious Diseases

§  Neurological Disorders

§  Neuromuscular Disorders

 §  Type of Molecule

§  Biologic

§  Small Molecule

 §  Target Pathway

§  Alternate Pathway

§  Classical Pathway

§  Lectin Pathway

§  Terminal Pathway

 §  Type of Therapy

§  Monotherapy

§  Combination Therapy

 §  Route of Administration

§  Intravenous

§  Oral

§  Subcutaneous

 §  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

 The research also includes detailed profiles of the key players (listed below) engaged in the development of next generation complement therapeutics; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments and an informed future outlook.

§  Amgen

§  CSL Behring

§  Innovent Biologics

§  Novartis

§  Regeneron

§  Roche

§  Sanofi

§  Takeda

§  UCB

 For additional details, please visit 

https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html

or email [email protected]

You may also be interested in the following titles:

1.      Gene Editing beyond CRISPR Market, 2022-2035

2.      Myeloid Cells Targeting Therapeutics Market, 2021-2035

3.      Thermostable Vaccines and Thermostable Biologics Market, 2021-2035

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415